Table 1.

Patient characteristics

PatientStage at diagnosisStage at studyPrior treatment
BinetRaiBinetRai
CLL1 CLB + pred  
CLL2 IV IV CLB + pred; flu 
CLL3 CLB  
CLL4 CLB + pred  
CLL5 CLB + pred 
CLL6 IV IV CLB; CHOP; etoposide 
CLL7 IV IV CLB; cyclo + pred 
CLL8 None 
CLL9 CLB; flu 
CLL10 III III None 
CLL11 None 
CLL12 II II None 
CLL13 None 
CLL14 None 
CLL15 III III None 
CLL16 None 
*CLL17 II IV CLB; CHOP; flu 
*CLL18 II CLB + flu 
CLL19 None 
CLL20 II II pred; CLB + pred; cyclo + vincristine + pred  
CLL21 CLB + pred 
PatientStage at diagnosisStage at studyPrior treatment
BinetRaiBinetRai
CLL1 CLB + pred  
CLL2 IV IV CLB + pred; flu 
CLL3 CLB  
CLL4 CLB + pred  
CLL5 CLB + pred 
CLL6 IV IV CLB; CHOP; etoposide 
CLL7 IV IV CLB; cyclo + pred 
CLL8 None 
CLL9 CLB; flu 
CLL10 III III None 
CLL11 None 
CLL12 II II None 
CLL13 None 
CLL14 None 
CLL15 III III None 
CLL16 None 
*CLL17 II IV CLB; CHOP; flu 
*CLL18 II CLB + flu 
CLL19 None 
CLL20 II II pred; CLB + pred; cyclo + vincristine + pred  
CLL21 CLB + pred 

CLB indicates chlorambucil; CHOP, cyclophosphamide + doxorubicin + vincristine + predniolone; pred, prednisolone; flu, fludarabine; cyclo, cyclophosphamide.

*

Both PB cells and node were studied.

Only node examined.

Only spleen examined.

Close Modal

or Create an Account

Close Modal
Close Modal